Palisade Bio shares more than double over 'fast track' tag for bowel function drug

Palisade Bio

22/11/2022 15:39

(Updates)
    ** Shares of drug developer Palisade Bio Inc  PALI.O  more
than double to $4.9
    ** Co says it received U.S FDA's "fast track" tag for its
experimental drug LB1148
    ** PALI says drug neutralizes digestive enzymes to
potentially reduce intestinal damage and accelerate return of
bowel function following abdominal surgery
    ** A fast track designation facilitates development and
expedites review of therapies with the potential to treat a
serious condition where there is an unmet medical need
    ** Including session's gain, stock down 92.5% YTD
 (Reporting by Sriparna Roy and Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))